GCR Life Sciences - Switzerland
A stable and comprehensible legal framework is of great importance, not only in crisis situations, but in general. Legal uncertainties are poison for the supply of a country with important medical goods. The life sciences sector has so far not raised any major competition law issues in Switzerland. Yet, recent jurisprudence as well as enacted and planned legislative amendments are not free of contradictions and ambiguities. The lack of an update of the Mutual Recognition Agreement and the related status of Switzerland as a third country vis-à-vis the EU brought additional uncertainties. The authors provide an overview of the current regulatory environment and discuss the implications of planned legislative changes.